Brief: Humanigen Receives Preliminary Topline Data From NIH/NIAID Study Of Lenzilumab In ACTIV-5/BET-B

Humanigen

13/07/2022 01:32

July 12 (Reuters) - Humanigen Inc  HGEN.O :
    * HUMANIGEN RECEIVES PRELIMINARY TOPLINE DATA FROM NIH/NIAID
STUDY
OF LENZILUMAB IN ACTIV-5/BET-B
    * SAYS TRIAL DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON
PRIMARY
ENDPOINT
    * SAYS THERE WERE NO NEW SAFETY SIGNALS ATTRIBUTED TO
LENZILUMAB
IN ACTIV-5/BET-B STUDY
    * DATA ALSO SHOWED A NON-SIGNIFICANT TREND TOWARD A
REDUCTION IN
MORTALITY IN OVERALL PATIENT POPULATION

Source text for Eikon:  ID:nBw6QxWPja 
Further company coverage:  HGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))